Shwachman-Diamond syndrome (SDS) is an inherited bone marrow failure and cancer predisposition syndrome that affects multiple organ systems. Mutations in the Shwachman-Bodian-Diamond syndrome (SBDS) gene are found in the majority of patients, but the molecular function of the SBDS protein product remains unclear. In this article, we review recent progress in the clinical and molecular characterization of SDS.
Introduction
Shwachman-Diamond syndrome (SDS) is an autosomal recessively inherited bone marrow failure syndrome originally characterized by neutropenia and pancreatic dysfunction [1, 2] . Further studies reported that the hematopoietic defect is not confined to neutropenia, but can also affect red cells and platelets. SDS patients have an increased risk of developing bone marrow aplasia, myelodysplastic changes, and leukemia (reviewed in [3 ] ). Additionally, patients may manifest abnormalities in multiple other organs, most notably in the bones, liver, heart, and immunologic system.
In 2003, Shwachman-Bodian-Diamond syndrome (SBDS), a gene highly conserved in eukaryotes and archaebacteria, was found to be mutated in patients with SDS [4 ] . Since then, SBDS mutations have been identified in approximately 90% of patients who manifest the clinical characteristics of the syndrome. Proteomic data implicated SBDS in RNA metabolism and ribosomal function [5, 6] . The Saccharomyces cerevisiae ortholog Sdo1p interacts with the ribosomal assembly protein Tif6p to regulate maturation of the 60S large ribosomal subunit and its joining to the 40S subunit to form the mature ribosome [7 ] . Consistent with a role in ribosomal function, human SBDS is concentrated in the nucleolus and co-sediments with the 60S large ribosomal subunit. Furthermore, SDS patient cells are more sensitive to inhibition of ribosomal RNA transcription [8, 9] . Additional functions for SBDS in mitosis are supported by data demonstrating that SBDS also localizes to the mitotic spindle, binds and stabilizes purified microtubules in vitro, and loss of SBDS leads to aneuploidy when mitotic checkpoints are inactivated [10 ] . A role for SBDS in chemotaxis has been postulated based on the observation that SBDS localizes to the pseudopods in Dictostyleum [11] and SDS patient neutrophils exhibit impaired chemotaxis in vitro, though whether this is a direct or indirect effect of SBDS loss remains to be clarified [12] . How the SBDS protein carries out these disparate functions is unclear because the precise molecular function(s) of the SBDS protein product remains to be deciphered.
In this article, we briefly highlight some of the most recent advances (focusing on those published in the past 18 months) in our understanding of the clinical spectrum of SDS and of the molecular function of the SBDS protein. For additional background, several prior comprehensive reviews are available [3 , 13, 14] .
Clinical spectrum
The complete spectrum of SDS clinical manifestations remains to be characterized. Recent clinical studies have provided a clearer picture of the progression of marrow disease in SDS [15] [16] [17] [18] [19] 20 ] , and better characterized its neurocognitive [21 ] and hepatic [22 ] symptoms.
Hematologic manifestations
Much of the information on the prevalence and natural history of SDS have been derived from cohort and crosssectional studies. The relative estimated allele frequencies of SDS (1/140 -from an estimated incidence of one in 76 538 live births, based on the relative frequency to cystic fibrosis patients in patients with pancreatic failure [23] ) and Fanconi anemia (1/100 to 1/300) [24, 25] suggest that SDS is likely more common than currently recognized. In the National Institutes of Health (NIH) registry, SDS (7%) is the fourth most common inherited bone marrow failure syndrome (IBMFS) after Fanconi anemia (27%), dyskeratosis congenita (20%), and Diamond-Blackfan anemia (DBA) (25%) [15] . In the Canadian Inherited Marrow Failure Study, SDS (27%) and Fanconi anemia patients are equally represented, and less than only DBA patients (31%), but more than severe congenital neutropenia (SCN) (8%) and dyskeratosis congenita (6%) [16] . In the Israeli Inherited Bone Marrow Failure Registry, SDS comprises a smaller proportion of patients -Fanconi anemia 52% and SDS 2%but this population-based registry may be skewed by the increased incidence of Fanconi anemia in the Ashkenazi Jewish population [17, 24] . As with any Registry study, referral biases may affect the relative frequencies of the different syndromes enrolled.
As in Fanconi anemia or dyskeratosis congenita, the marrow disease in SDS can progress leading to aplastic anemia, myelodysplastic syndrome (MDS), or acute myelogenous leukemia (AML). The definition of MDS in SDS patients was not consistent between studies and thus generalizations are difficult. Previous estimates of the rate of transformation to MDS or AML gave rates of 18.8% at 20 years and 36.1% at 30 years from a group of 55 SDS patients in the French registry [26] . Similarly, the crude rate of MDS/AML of SDS patients was approximately 1% per year from a limited number of SDS patients in the Severe Chronic Neutropenia International Registry [27] . In comparison to the other IBMFS tracked by the Canadian registry, the cumulative rate of transformation for SDS (18%) was intermediate between Fanconi anemia (41%) and dyskeratosis congenita (13%), SCN (10%) and DBA (0%) [16] . In contrast, none of the 17 SDS patients in the NIH registry nor any of the three in the Israeli registry developed MDS or AML [15, 17] . Importantly, although the median age of the NIH SDS patients was 14 years [15] , those SDS patients in the Canadian study who transformed did so at a median age of 20 years [16] , and those in the French cohort transformed at a median age of 19.1 years, with most occurring after 20 years [26] . These data indicate that the pace and likelihood of malignant transformation in SDS is lower than that in Fanconi anemia.
In addition to developing clonal myeloid disease such as MDS and AML, SDS patients also have a propensity to acquire characteristic cytogenetic clones that may persist without immediate further evolution of their marrow disease. Notably, clones of isochromosome i(7)(q10) may wax and wane for years without malignant transformation [28] . Using microsatellite analysis, Minelli et al. [18] determined the parental origin of the isochromosome 7 clones present in eight patients who were compound heterozygotes for mutations in SBDS. All eight patients carried the c.258þ2T>C allele, which disrupts the donor splice site in intron 2 and leads to a truncated protein, but allows the production of a small amount of full-length protein, as well as an allele that introduces an in-frame premature stop codon. In all eight cases, the isochromosome was derived from the parental chromosome containing the splicing mutant. This result suggests that the selective advantage of cells having three copies of an allele with partial expression of SBDS may give rise to the i(7)(q10) clones.
Two recent reports provide additional insights into the natural history of a second commonly seen cytogenetic abnormality in SDS -del(20)(q11) [19, 20 ] . The first describes two patients who developed del(20)(q11q13) clones at an age of 12 years, and whose clones persisted for over 6 years without progression to MDS or AML. In one patient, the positive clones progressively increased over 6 years until all marrow cells were positive. The authors detected del(20q) cells in all hematopoietic lineages from both patients, leading them to conclude that the del(20)(q11q13) clones arose in a totipotent cell, which retains its ability to differentiate despite the abnormal karyotype [19] . The second is a report of the cytogenetic findings of a cohort of 37 SDS patients, 18 of whom developed abnormal cytogenetic clones. All of the Shwachman-Diamond syndrome Huang and Shimamura 31 Key points SDS is likely more common than currently recognized. Some cytogenetic changes in SDS do not, in isolation, signal imminent progression to MDS or leukemia.
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clones involved either chromosome 7 or chromosome 20. Of the chromosome 7 abnormalities, 10 were isochromosome i(7q)(10), one was a deletion del(7)(q22q32), and one had additional materials add7(p?). Of the six chromosome 20 clones, all begin as del(20)(q11), but two developed subclones with additional alterations. The patients had been followed for 3 months to 9 years and at the time of the report, eight were stable, four had increased, and one had decreased; only the patient with the add7(p?) clone developed MDS. Importantly, no AML developed despite the fact that all the del(20)(q11) clones included a region commonly deleted in MDS and AML. Thus, the acquisition of either isochromosome i(7)(q10) or the deletion del(20)(q11) is likely a relatively benign event, rather than a herald of imminent progression to MDS or AML. Furthermore, the acquisition of the abnormal cytogenetic clones appear to be an age-related phenomenon in SDS patients as the frequency of such clones increase with age -they were present in four of 17 patients below 10 years, eight of 14 between 10 and 20, and in four of four of those older than 20 years [20 ] .
Neurocognitive impairment
Although SDS was first described over 45 years ago, due to its rarity and phenotypic variability, its clinical spectrum is still being fully characterized. In follow-up to prior reports of neurocognitive impairment in SDS patients [29] , Kerr et al. [21 ] performed systematic neuropsychological assessments of the largest cohort of SDS patients to date. Thirty-four children with SDS from Canada and the United States were compared with 13 siblings and with 20 patients with cystic fibrosis. Although SDS patients exhibited a wide range of abilities -from severely impaired to very superior in some measures -as a group, SDS patients generally had significant impairments in intelligence, language abilities, perceptual skills, and academic achievement. On measures of attention, SDS patients scored lower than cystic fibrois patients, but not sibling controls. The authors note that one in five SDS patients met the diagnostic criteria for intellectual disability (<second percentile), and that the proportion (6%) of the children diagnosed with pervasive developmental disorder is much higher than the expected number (one out of every 165). This study highlights an underappreciated facet of SDS, suggests a role for SBDS in neurodevelopment, and raises the importance of early neurocognitive assessment and intervention.
Hepatopathy
In addition to pancreatic insufficiency, SDS patients may manifest additional gastrointestinal alterations, most prominently in the liver (reviewed in [3 ]). The liver manifestations were further characterized in a cohort of 12 SDS patients in a population-based study from Finland [22 ] . Consistent with previous reports, they found that elevated transaminases and hepatomegaly occurred early in life, but normalized over time. In contrast, more than half of the patients had elevated bile acid levels at the time they were tested for the study. The authors also provide a longitudinal assessment of liver imaging changes, showing that hepatomegaly was present only in patients younger than 3 years of age, but that all three patients older than 30 years of age had developed hepatic microcysts. Thus, it appears that the elevated transaminases and hepatomegaly present in some young SDS patients resolve over time, but cholestasis may persist, and hepatic microcysts may develop in older patients [22 ] .
Molecular pathophysiology SBDS appears to be a multifunctional protein implicated in several important cellular pathways. There is accumulating evidence for its role in ribosomal function [30,31 ,32,33 ,34,35] as well as in microtubule binding [36] and actin polymerization [37] . Moreover, several recent studies posit additional functions [35, 38, 39] . In mouse models, deficiency of SBDS expression in marrow osteoprogenitor cells leads to hematologic and skeletal abnormalities [40 ] .
RNA metabolism and ribosomal function
Recent studies provide additional insights into SBDS structure and further illuminate its interaction with RNA. Ng et al. [30] solved the crystal structure of the Methanothermobacter SBDS to 1.75 Å resolution and de Oliveira et al. [31 ] determined the structure of human SBDS by solution nuclear magnetic resonance (NMR). Both groups describe a tripartite domain structure consisting of an amino terminal FYSH domain, a central three-helical domain, and a carboxy-terminal ferrodoxinlike domain, linked by flexible connectors, similar to that previously determined for Archaeoglobus fulgidus [6,30,31 ,41] . NMR studies indicated that the amino terminal domain is the site of RNA-SBDS interactions, and moves independently of domains II and III, which act as one unit [31 ] . Additionally, the budding yeast ortholog Sdo1p was shown to co-immunoprecipitate with a number of ribosomal RNA species and their processing intermediates [32] . In human, methanobacter, and yeast systems, RNA binding does not appear to be sequence specific, though there may be increased affinity for poly adenine and uracil (AU) tracts in the human and yeast, and with GC-rich sequences in yeast [31 ,32] .
Because both SDS and DBA have been linked to ribosomal dysfunction, Moore et al. [33 ] compared the effect of yeast models of DBA (RPL33A) and SDS (SDO1) on the ribosome. Both mutants exhibit a selective decrease in the 60S large ribosomal subunit and an accumulation of half-mer polysomes containing stalled 48S initiation complexes, but the defect in SDS appears to be downstream to that of DBA. Unlike the DBA model, where incompletely assembled ribosome precursors are rapidly degraded, in SDS, 60S particles accumulate in the nucleoplasm. These results support the role previously posited for Sdo1p in Tif6p recycling and the maturation and joining of the 60S ribosomal subunit [7 ] , although half-mer polysomes were not observed in the earlier study.
Further evidence of a link between SBDS and ribosomal function or RNA metabolism comes from expression microarray and protein interaction studies. Gene-expression profiles in SDS patient bone marrow cells show that the most deregulated gene cluster among pathways known to be defective in bone marrow failure syndromes was that for translation [34] . The Methanothermobacter SBDS co-purifies with ribosomal subunits Rpl1, 2, and 14 [30] ; similarly FLAG-tagged human SBDS interacts with a number of ribosomal subunits, two heterogenous nuclear ribonucleoproteins, a nucleolar RNA helicase, and nucleolar proteins nucleophosmin and nucleolin [35] . In the yeast two-hybrid assay, Sdo1p partners with Rpl3p, translation elongation factor Eft2p, nucleolar protein Nip7p, the RNA helicase Prp43p, and two of its interaction partners, Spp382p/Ntr1p and Asc1p [32] .
Non-RNA functions
Recent investigations also provide additional evidence that SBDS plays roles aside from ribosome maturation and RNA metabolism. Orelio and Kuijpers [36, 37] examined the localization of SBDS in neutrophils, CD34 þ hematopoietic progenitor cells, and adherent and leukemic cell lines. They found that SBDS is present in the nucleus, perinuclear area, and cytoplasm. Consistent with the previously demonstrated mitotic function of SBDS [10 ] , they also found that SBDS co-localizes with microtubules, microtubule organizing centers, and centrosomes in both primary hematopoietic progenitors and various cell lines, and that SBDS binds microtubules in vitro [36] . Additionally, in activated and adherent neutrophils and a leukemic cell line, SBDS co-localizes with Factin and Rac2 in cellular protrusions [37] , similar to that described for Dictyostelium during chemotaxis [11] , and Factin polymerization is disturbed and its polarization delayed in SDS patient neutrophils in response to chemoattractants [37] . Thus, these data support a role for SBDS in both microtubule and actin-dependent cellular processes.
Other recent studies implicate SBDS in additional possible functions. A yeast two-hybrid screen identified an interaction between the carboxyl-terminus of SBDS with the cytosolic portion of CLN3, the transmembrane protein mutated in juvenile neuronal ceroid lipofuscinosis (Batten disease). This interaction was confirmed by coimmunoprecipitation and immunofluorescence in mammalian cell lines, and in the yeast model with Btn1p (the yeast CLN3 ortholog) and Sdo1p [38] . Although the function of CLN3/BTN1 is not well understood, BTN1 plays a role in vacuolar pH regulation. Interestingly, deletion of SDO1 alters vacuolar pH and the level of vacuolar ATPase proteins, an effect that is reversed by TIF6 mutants that suppress the sdo1D slow growth phenotype [38] . Second, FLAG-tagged human SBDS also co-purified with proteins involved in DNA metabolism, including DNA-dependent protein kinase (DNA-PK), replication protein A 1 (RPA1), histones, and X-ray repair cross-complementing protein 5 (XRCC5) [35] . These studies suggest that SBDS may play previously unsuspected roles in vacuolar pH regulation and DNA metabolism.
Previous studies described a role for SDS in both marrow hematopoietic cells [42, 43] and in marrow stromal cells [42] . Unexpected insights into SBDS function in the marrow stroma were elicited from the examination of mice wherein expression of Dicer1, an RNaseIII endonuclease required for microRNA biogenesis and RNA processing, was knocked down specifically in osteoprogenitor cells. This resulted in reduced SBDS expression in osteoprogenitor cells and an increased rate of myelodysplasia and myeloid leukemia. Furthermore, selective deletion of SBDS in mouse osteoprogenitors results in mice exhibiting boney abnormalities, leucopenia, lymphopenia, increased marrow vascularity, micromegakaryocytes, and dysplastic (although not decreased) neutrophils [40 ] . Given the skeletal anomalies associated with SDS, a role for SBDS in osteoprogenitor cells is intriguing. Furthermore, these results suggest that normal hematopoiesis requires proper SBDS expression in stromal cells. Interestingly, expression microarray analysis of SBDS-depleted human cell lines identified vascular endothelial growth factor A and osteoprotegerin, two secreted proteins that affect osteoclast differentiation and vascular formation, as the most significantly upregulated genes [39] . The impact of SBDS on human marrow stromal function in vivo remains unclear, as patients with SDS have not manifested high rates of engraftment failure during hematopoietic stem cell transplant (reviewed in [44] ). The long-term follow-up of SDS patients who have undergone stem cell transplant may provide important clues to the clinical impact of stromal cell SBDS expression on hematopoiesis.
Conclusion
Careful descriptions of the natural history of SDS and of its effect on multiple involved organs are providing crucial information for counseling patients and families on outcomes and treatments choices, as well as for timely assessments and interventions.
The SBDS protein participates in numerous key cellular functions, although its precise molecular functions remain to be elucidated. How these apparently different functions of SBDS contribute to disease pathogenesis remains an important area of investigation.
